Targets › SLC10A1
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease.
As a major transporter of conjugated bile salts from plasma into the hepatocyte, it plays a key role in the enterohepatic circulation of bile salts necessary for the solubilization and absorption of dietary fat and fat-soluble vitamins. It is strictly dependent on the extracellular presence of sodium. (UniProt, Q14973)
Open in Phaseline: the race on SLC10A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai HEP Pharmaceutical | Hepalatide (L47) Bile acid transporter inhibitor | SLC10A1 | Phase 2 | Hepatitis D | – |
Hepatitis D (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.